Drug Resistant Kinase Mutations

Within almost all kinases, a molecular control known as the activation switch governs whether the kinase is in the inactive or the active state. Most of the time kinases are in an inactive state and are triggered into the active state when they are needed to direct normal cellular functions. Mutations within kinases, particularly those that involve the activation switch region, can cause uncontrolled kinase signaling within the cell. In addition, kinases may acquire further mutations during treatment with traditional kinase inhibitor drugs that confer resistance to these drugs.

Learn more about our tumor-targeted drug candidate, DCC-2618.

Kinase Switch Control Inhibitors as Tumor-targeted Therapies

Deciphera’s switch control inhibitors block mutated kinase signaling to prevent aggressive tumor growth and proliferation, even in cancers that are resistant to other kinase inhibitors.